Ikarian Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Ikarian Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-350,000	Closed	-$4.83M	–	172
2022 Q2	$4.83M	Buy	+350,000	New	+$5.6M	0.88%	38
2021 Q2	–	Sell	-100,000	Closed	-$2.31M	–	312
2021 Q1	$2.31M	Buy	+100,000	New	+$2.79M	0.08%	192
2020 Q3	–	Sell	-150,000	Closed	-$7.19M	–	217
2020 Q2	$7.19M	Buy	150,000 +100,000	+200%	+$7.73M	0.57%	57
2020 Q1	$3.15M	Sell	50,000 -14,900	-23%	-$1.34M	0.24%	80
2019 Q4	$8.04M	Buy	+64,900	New	+$5.81M	1.3%	21

Other funds holding ICPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Ikarian Capital's ICPT Position: Q3 2023 in Review

Ikarian Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 160,200 shares — an estimated $1.77M sold.

Ikarian Capital first reported a position in ICPT in Q1 2021 and held it in 10 quarters. The position peaked at $1.77M in Q2 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

Ikarian Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 160,200 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.77M.
Ikarian Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2021 and held it in 10 quarters.
Ikarian Capital's Intercept Pharmaceuticals, Inc. position peaked at $1.77M in Q2 2023.
146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.